Reaction
Application Site Discomfort reporting signals
As of the last recalculation, Application Site Discomfort appears in 1,780 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is PEGFILGRASTIM (PRR 64.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pegfilgrastim | 417 | 64.2 | 64.5 |
| Minoxidil Foam 5% (Womens) | 64 | 23.5 | 23.5 |
| Minoxidil | 73 | 19.8 | 19.8 |
| Lidocaine 4% | 78 | 17.5 | 17.5 |
| Oxybutynin | 42 | 17.2 | 17.2 |
| Lidocaine | 78 | 16.3 | 16.3 |
| Etonogestrel | 61 | 15.4 | 15.5 |
| Nicotine | 49 | 14.5 | 14.6 |
| Methylphenidate | 34 | 14.0 | 14.0 |
| Glycerin, Lidocaine | 16 | 13.5 | 13.5 |
| Docosanol | 16 | 12.9 | 12.9 |
| Estradiol | 86 | 12.2 | 12.2 |
| Miconazole Nitrate | 7 | 9.4 | 9.4 |
| Estradiol Gel 0.1% | 35 | 9.2 | 9.2 |
| Estradiol Transdermal | 35 | 9.2 | 9.2 |
| Crisaborole | 7 | 8.6 | 8.6 |
| Diclofenac Potassium | 5 | 5.4 | 5.4 |
| Buprenorphine | 42 | 5.4 | 5.4 |
| Guanfacine | 3 | 4.5 | 4.5 |
| Evolocumab | 18 | 1.3 | 1.3 |